Q4 2024 Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in ...

Imagine yourself as a passive income investor looking for a medical stock with significant share growth potential. Wall ...

Notably, Merck's Winrevair pulmonary arterial hypertension (PAH) medication is on track to be the company's next blockbuster drug, already delivering $419 million in sales in just the first two ...

Great investments are even better and more fruitful when you can buy them at a discount. Lots of investors enjoy keeping an ...

Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

I also want to point out the excellent news related to Winrevair (sotatercept), which is, in turn, the flagship of Merck's cardiovascular franchise. On January 30 of this year, it announced that ...

In the third quarter, Merck reported a decline of 11% in Gardasil sales to $2.31 billion. The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated sales ...

Merck reported adjusted earnings of $1.72 per ... to $15.62 billion driven by Keytruda, new products like Winrevair and strong performance of the Animal Health segment, partially offset by lower ...

Medicare Part D redesign is expected to hurt sales by approximately $400 million, primarily affecting Winrevair and oncology products, including Welireg, Lynparza and Lenvima. Merck expects top ...